Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
IMPACT OF LIVER-DISEASE AND HEPATITIS INFECTIONS ON ALLOGENEIC BONE-MARROW TRANSPLANTATION IN EUROPE - A SURVEY FROM THE EUROPEAN BONE-MARROW TRANSPLANTATION (EBMT) GROUP INFECTIOUS-DISEASES WORKING PARTY
Autore:
LOCASCIULLI A; ALBERTI A; DEBOCK R; CORDONNIER C; EINSELE H; ENGELHARD D; GRUNDY J; REUSSER P; RIBAUD P; LJUNGMAN P;
Indirizzi:
UNIV MILAN,NUOVO OSPED S GERARDO,PEDIAT CLIN,VIA DONIZETTI 106 I-20052 MONZA ITALY UNIV MILAN,PEDIAT CLIN MILAN ITALY
Titolo Testata:
Bone marrow transplantation
fascicolo: 5, volume: 14, anno: 1994,
pagine: 833 - 837
SICI:
0268-3369(1994)14:5<833:IOLAHI>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
VENOOCCLUSIVE DISEASE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
8
Recensione:
Indirizzi per estratti:
Citazione:
A. Locasciulli et al., "IMPACT OF LIVER-DISEASE AND HEPATITIS INFECTIONS ON ALLOGENEIC BONE-MARROW TRANSPLANTATION IN EUROPE - A SURVEY FROM THE EUROPEAN BONE-MARROW TRANSPLANTATION (EBMT) GROUP INFECTIOUS-DISEASES WORKING PARTY", Bone marrow transplantation, 14(5), 1994, pp. 833-837

Abstract

This survey investigated allogeneic bone marrow transplantation (BMT)policy in European BMT units by questionnaire, in relation to pre-transplant liver disease, It also assessed diagnostic standards for viralhepatitis infections and their prevalence in BMT candidates, Sixty-three EBMT centers from 22 countries participated in the survey, Median pre-transplant prevalences of HBsAg and anti-HCV positivity were 3.5% (range 0-15%) and 5% (range 0-45%), respectively, Forty-six (73%) centers adopt the policy of cancelling or postponing BMT in patients with ALT abnormalities but in four of these centers, BMT is not delayed when progressive disease or acute leukemia is present, In 17 institutions(27%) BMT was reported to be carried out irrespective of transaminasevalues, Data on fatal post-BMT liver disease were provided by 45 centers, The overall mortality rate for liver failure was 4.5% (258 of 5788) with no differences between centers performing or not performing BMT in cases of ALT elevation. These results indicate that there is strong concern in most European BMT units about performing BMT in the presence of ALT elevation and prospective studies on its real impact on fatal post-BMT liver disease should be conducted.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 15/07/20 alle ore 05:36:22